IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Phase 3 · 211 sites
Search the registry
2,585 studies found
Phase 3 · 211 sites
Phase 1 / Phase 2 · 15 sites
Phase 2 · 1 site
Potential match only. Final eligibility is determined by the study team.